^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    veligrotug (VRDN-001)

    i
    Other names: VRDN-001, AVE1642, ZB001
    Associations

    News

    Trials
    Company:
    AbbVie, Kissei, Sanofi, Viridian Therap, ZAI Lab, Zenas BioPharma
    Drug class:
    IGF-1R antagonist
    Associations

    News

    Trials
    4ms
    An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) (clinicaltrials.gov)
    P3, N=188, Completed, Viridian Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    veligrotug (VRDN-001)
    6ms
    VRDN-001-302: An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 (clinicaltrials.gov)
    P3, N=143, Completed, Viridian Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    veligrotug (VRDN-001)
    7ms
    A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) (clinicaltrials.gov)
    P3, N=113, Completed, Viridian Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    veligrotug (VRDN-001)
    10ms
    Study of ZB001 in Chinese Patients With Thyroid Eye Disease (clinicaltrials.gov)
    P1, N=17, Completed, Zenas BioPharma (USA), LLC | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    veligrotug (VRDN-001)
    10ms
    VRDN-001-302: An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE) (clinicaltrials.gov)
    P3, N=143, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jul 2025
    Enrollment closed • Trial completion date
    |
    veligrotug (VRDN-001)
    10ms
    STRIVE: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=231, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    veligrotug (VRDN-001)
    over1year
    An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) (THRIVE-2) (clinicaltrials.gov)
    P3, N=188, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    veligrotug (VRDN-001)
    over1year
    A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=212, Recruiting, Viridian Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    veligrotug (VRDN-001)
    almost2years
    A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=154, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    veligrotug (VRDN-001)
    almost2years
    A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=212, Not yet recruiting, Viridian Therapeutics, Inc.
    New P3 trial
    |
    veligrotug (VRDN-001)
    almost2years
    An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies (clinicaltrials.gov)
    P3, N=143, Recruiting, Viridian Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Feb 2023
    Enrollment open • Trial initiation date
    |
    veligrotug (VRDN-001)
    2years
    Study of ZB001 in Chinese Patients With Thyroid Eye Disease (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Zenas BioPharma (USA), LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    veligrotug (VRDN-001)